文献速递心律失常

经静脉导线拔除术后植入全皮下心律转复除颤器的可行性研究

[Feasibility study of subcutaneous implantable cardioverter-defibrillator after transvenous lead extraction].
PubMed 文献 · Zhonghua Xin Xue Guan Bing Za Zhi · 2025-01-01

该回顾性研究纳入2015年6月至2023年10月在北京大学人民医院植入S-ICD的27例患者,比较TLE术后植入组(12例)与新植入组(15例)的基线特征、适应证及随访结果。结果显示所有患者手术成功,随访期间无并发症或死亡,设备功能正常,提示S-ICD对TLE术后患者安全有效。

要点

  • TLE术后植入S-ICD的主要适应证为感染高风险(9/12)。
  • 全部患者S-ICD植入成功,18例除颤阈值测试均成功。
  • 随访期间无并发症或死亡,设备功能正常,7次达到除颤标准的事件均获有效治疗。

核心结论

  • S-ICD对TLE术后患者是安全有效的治疗方案,装置功能与随访结果与新植入S-ICD患者具有一致性。

研究设计与样本

  • 回顾性研究,连续纳入2015年6月至2023年10月于北京大学人民医院植入S-ICD的27例患者。
  • 按S-ICD植入前是否接受TLE分为TLE组(12例)和新植入组(15例)。
  • 收集并比较两组基线特征、S-ICD适应证、除颤阈值测试结果、并发症及术后随访情况。

主要发现

  • 共纳入27例患者,年龄(49.2±14.2)岁,男性19例。
  • 新植入组年龄更小[(43.3±13.7)岁比(55.6±12.0)岁,P=0.013]。
  • TLE组主要适应证为感染高风险(9/12),新植入组主要为年轻(11/15)。
  • 所有患者S-ICD植入成功,18例完成除颤阈值测试且全部成功。
  • TLE组随访时间更长[42(19,60)个月比12(3,28)个月,P=0.001],随访期间无并发症或死亡,共记录17次室速或室颤事件,其中7次达到除颤标准且全部获有效治疗。

临床怎么用

  • 对于TLE术后需植入ICD的患者,S-ICD可作为安全有效的治疗选择。
  • TLE术后患者选择S-ICD时,感染高风险是主要考虑因素。

局限性

  • 本研究为单中心回顾性研究,样本量较小(27例)。
  • 两组随访时间差异显著,可能影响结局比较。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To evaluate the clinical feasibility of subcutaneous implantable cardioverter-defibrillator (S-ICD) implantation following transvenous lead extraction (TLE). Methods: This was a retrospective study. Consecutive patients who underwent S-ICD implantation at Peking University People's Hospital between June 2015 and October 2023 were enrolled. Patients were divided into the TLE group and the newly implanted group based on whether they received TLE prior to S-ICD implantation. Baseline characteristics, S-ICD indication, defibrillation threshold test results, complications, and postoperative follow-up data were collected and compared between the two groups. Results: A total of 27 patients were included, aged (49.2±14.2) years, including 19 males. There were 12 patients in the TLE group and 15 in the newly implanted group. Compared with the TLE group, patients in the newly implanted group were younger ((43.3±13.7) years vs. (55.6±12.0) years, P=0.013). The main S-ICD indication in the TLE group was high infection risk (9/12), whereas in the newly implanted group it was younger age (11/15). All patients underwent successful S-ICD implantation, with 18 patients completing defibrillation threshold testing (all successful). Additionally, the TLE group had longer follow-up duration than the newly implanted group (42 (19, 60) months vs. 12 (3, 28) months, P=0.001). No complications or deaths occurred during follow-up, with normal device function in both groups. A total of 17 ventricular tachycardia or fibrillation events were recorded, of which 7 met defibrillation criteria and all received effective therapy. Conclusion: S-ICD demonstrates safety and efficacy as a therapeutic option for patients after TLE, with comparable device functionality and follow-up outcomes to patients with newly implanted S-ICD. 目的: 评估经静脉导线拔除(TLE)术后植入全皮下植入式心律转复除颤器(S-ICD)的临床可行性。 方法: 本研究为回顾性研究。连续纳入2015年6月—2023年10月于北京大学人民医院植入S-ICD的患者,根据S-ICD植入前是否接受TLE术将入选患者分为TLE组和新植入组,收集并比较2组患者的基线特征、S-ICD适应证、除颤阈值测试结果、并发症及术后随访情况。 结果: 共纳入27例患者,年龄(49.2±14.2)岁,男性19例。TLE组12例,新植入组15例。与TLE组相比,新植入组患者的年龄更小[(43.3±13.7)岁比(55.6±12.0)岁,P=0.013]。TLE组患者S-ICD的主要适应证为感染高风险(9/12),而新植入组的主要适应证为年轻(11/15)。所有患者S-ICD植入手术成功,共18例患者进行除颤阈值测试(全部成功)。此外,TLE组随访时间较新植入组长[42(19,60)个月比12(3,28)个月,P=0.001]。随访期间无并发症或死亡发生,2组患者的设备功能均正常,共记录17次室性心动过速或心室颤动事件,其中7次达到除颤治疗标准且全部获得有效除颤治疗。 结论: S-ICD对于TLE术后患者是一种安全且有效的治疗方案,其装置功能和术后随访结果与新植入S-ICD患者相比具有一致性。.

来源:Zhonghua Xin Xue Guan Bing Za Zhi,查看原文。版权归原作者所有。

引用

  1. Yuan CZ, Ze F, Li D, et al. [Feasibility study of subcutaneous implantable cardioverter-defibrillator after transvenous lead extraction]. Zhonghua Xin Xue Guan Bing Za Zhi. 2025. PMID: 41139650. doi:10.3760/cma.j.cn112148-20250828-00610

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。